Kalaris Therapeutics

Acquired

Your vision, our mission

Kalaris Therapeutics is a biotech company in Berkeley Heights, United States. It has raised $53.8M across 2 rounds, most recently a $50.0M Corporate Round in December 2025.

Headquarters
Berkeley Heights
Business Model
B2B
Total Funding
$53.8M
Last Round
$50.0M Corporate RoundDec 2025
Rounds
2
Type
Public
Acquisition Date
Mar 2025

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 2 funding rounds and 2 investors for this company. to use credits for reveals, or explore the API.

About

Kalaris Therapeutics is a clinical-stage biopharmaceutical company developing treatments for prevalent retinal diseases with major unmet medical needs, including wet AMD, diabetic eye disease, and retinal vein occlusion. Its lead asset, TH103, is an investigational dual-targeting biologic designed for extended intraocular retention and enhanced VEGF inhibition, aiming to reduce the frequent clinic visits current therapies require. Kalaris is headquartered in Berkeley Heights, New Jersey, and is backed by veteran biopharma investors.

Funding & Exit History

Data from Indexed.vcUpdated
Corporate RoundCorporate RoundDec 2025
$50.0M

2 more events

  • Merger2025
  • Convertible2024

Funding: Convertible Note through Corporate Round. Amounts, valuations, and investors where available.

Investors

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

  • Cloud/Infrastructure ×1
  • Marketing & SEO ×1

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Companies in related industries

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Kalaris Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/kalaris-therapeutics"><img src="https://indexed.vc/api/badge/company/kalaris-therapeutics" alt="Kalaris Therapeutics on Indexed.vc" width="260" height="76" /></a>